Can-Fite BioPharma's Namodenoson gains FDA approval for compassionate use in pancreatic cancer; Phase IIa trial underway in Israel. Can-Fite BioPharma Ltd. announced that major U.S. medical centers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback